3B BLACKBIO DX LTD.

Makes and sells molecular diagnostic PCR kits and reagents under the TRUPCR brand for infectious diseases, alongside a smaller agrochemicals line. The diagnostics business runs as open-kit/reagent kits (not closed systems, sample-to-answer, or point-of-care platforms) and sells through distributors across 70+ countries to over 1,000 customers. Two international subsidiaries anchor the export push: TRUPCR Europe (UK), with FY26 sales of GBP 1.75M (INR 20.67 crore) at roughly 40% CAGR over four years, and Coris BioConcept (Belgium), acquired in August 2025 and consolidated for seven months in FY26 with sales of INR 35.91 crore and PAT of INR 8.76 crore helped by a one-time HAT order. India remains the home market, where the company holds about 15% share of a molecular diagnostics market sized at INR 500–600 crore and growing 8–10% annually. Inputs are dominated by materials (25.2% of FY26 revenue) and employees (16.9%), with depreciation at 3.6% and capex at 18% of revenue; the FY26 consolidated EBITDA margin was 58.0% with PAT of INR 59.93 crore on revenue of INR 141.92 crore. A US FDA submission is underway for the Resist-5 AMR product targeting FY28 launch, IVDR transition for European SKUs is in progress ahead of the May 2026 EU deadline, and roughly INR 230–250 crore of cash is earmarked for further M&A with 2–3 targets under discussion. AR · MarketPing reader · 2026-08-02

Revenue streams, as the annual report describes them. Diagnostic Kits (Molecular Diagnostics / TRUPCR PCR kits and reagents), Agrochemicals, TRUPCR Europe (UK subsidiary), Coris BioConcept (Belgium subsidiary, consolidated from Aug 2025). Asset-light molecular diagnostics with growing international footprint built partly via acquisitions

Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)